Drug Trial Radar · NCT05249127
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
Last checked: Nov 20, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Apr 11, 2022
Primary completion
Aug 8, 2023
Study completion Aug 8, 2023
Sponsor
- Lead sponsor
- Clarity Pharmaceuticals LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.
Conditions
- Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions
64Cu-SAR-bisPSMADrug
64Cu-SAR-bisPSMA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: up to 7 days post injection
- Participant-level Correct Detection Rate (CDR)- Day 0Time frame: Day 0 (1- 4 hours) post injection
- Participant-level CDR- Day 1Time frame: Day 1 (24+/-6 Hours) post injection
- Region-level Positive Predictive Value (PPV)- Day 0Time frame: Day 0 (1- 4 hours)
- Region-level PPV- Day 1Time frame: Day 1 (24 +/- 6 hours)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Tower Urology
Los Angeles, California
GU Research Network
Omaha, Nebraska
New Mexico Cancer Center
Albuquerque, New Mexico
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Urology San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.